OTCMKTS:ARTH - Arch Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.2899 0.00 (-0.03 %) (As of 05/22/2019 04:00 PM ET)Previous Close$0.29Today's Range$0.28 - $0.2952-Week Range$0.27 - $0.69Volume452,975 shsAverage Volume283,073 shsMarket Capitalization$47.53 millionP/E RatioN/ADividend YieldN/ABeta-0.21 ProfileAnalyst RatingsChartEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts. Receive ARTH News and Ratings via Email Sign-up to receive the latest news and ratings for ARTH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ARTH Previous SymbolNASDAQ:ARTH CUSIPN/A CIK1537561 Webhttp://www.archtherapeutics.com/ Phone617-431-2313Debt Debt-to-Equity RatioN/A Current Ratio8.57 Quick Ratio13.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net Income$-4,810,000.00 Net MarginsN/A Return on Equity-886.17% Return on Assets-138.88%Miscellaneous Employees8 Outstanding Shares163,947,000Market Cap$47.53 million Next Earnings Date5/23/2019 (Estimated) OptionableNot Optionable Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions What is Arch Therapeutics' stock symbol? Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH." How were Arch Therapeutics' earnings last quarter? Arch Therapeutics Inc (OTCMKTS:ARTH) issued its earnings results on Tuesday, May, 2nd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). View Arch Therapeutics' Earnings History. When is Arch Therapeutics' next earnings date? Arch Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 23rd 2019. View Earnings Estimates for Arch Therapeutics. What price target have analysts set for ARTH? 4 equities research analysts have issued twelve-month price objectives for Arch Therapeutics' shares. Their predictions range from $1.25 to $2.50. On average, they anticipate Arch Therapeutics' stock price to reach $1.8750 in the next twelve months. This suggests a possible upside of 546.8% from the stock's current price. View Analyst Price Targets for Arch Therapeutics. What is the consensus analysts' recommendation for Arch Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arch Therapeutics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arch Therapeutics. What are Wall Street analysts saying about Arch Therapeutics stock? Here are some recent quotes from research analysts about Arch Therapeutics stock: 1. According to Zacks Investment Research, "Arch Therapeutics, Inc. is a medical device company. It develops products that make surgery and interventional care faster and safer by using an approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The Company's lead product candidate includes AC5 (TM), a biocompatible synthetic peptide, to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics, Inc. is headquartered in Wellesley, Massachusetts. " (5/21/2019) 2. LADENBURG THALM/SH SH analysts commented, "We expect the next months to be equally, if not more productive, as we believe European approval is likely by May 28 and we look for regulatory feedback from management on its next candidate, AC5 Surgical Hemostat, being developed for its most valuable indication(s), internal surgical procedures. We believe management is conducting in 2Q’19 pre-IDE meetings with the FDA to design clinical trials that will test this new device in likely several surgical procedures. We anticipate such plans (including the as-of-yet undisclosed, specific surgery types) to be disclosed in coming months, followed by trial initiations ~YE’19." (5/15/2019) 3. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We utilize a risk- adjusted net present value (rNPV) driven by a discounted cash flow (DCF)-based analysis to value Arch Therapeutics shares." (3/18/2019) Has Arch Therapeutics been receiving favorable news coverage? Headlines about ARTH stock have been trending somewhat positive on Wednesday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arch Therapeutics earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an effect on the company's share price in the immediate future. Who are some of Arch Therapeutics' key competitors? Some companies that are related to Arch Therapeutics include Alphatec (ATEC), Endologix (ELGX), T2 Biosystems (TTOO), iCAD (ICAD), Sensus Healthcare (SRTS), RenovaCare (RCAR), Apollo Endosurgery (APEN), Nuvectra (NVTR), Motus GI (MOTS), CAS Medical Systems (CASM), STRATA Skin Sciences (SSKN), Repro-Med Systems (REPR), Invo Bioscience (IVOB), Pro-Dex (PDEX) and RA Medical Systems (RMED). What other stocks do shareholders of Arch Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arch Therapeutics investors own include Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), POET Technologies (POETF), Aptose Biosciences (APTO), Actinium Pharmaceuticals (ATNM), Bellerophon Therapeutics (BLPH), Aurinia Pharmaceuticals (AUPH), Reshape Lifesciences (RSLS), Antares Pharma (ATRS) and Corbus Pharmaceuticals (CRBP). Who are Arch Therapeutics' key executives? Arch Therapeutics' management team includes the folowing people: Dr. Terrence W. Norchi, Chairman, Pres, CEO, Sec. & Director (Age 54)Mr. Richard E. Davis, CFO & Treasurer (Age 61)Dr. Avtar S. Dhillon, Bus. Advisor (Age 57)Mr. Rutledge Ellis-Behnke, Co-Founder & Scientific AdvisorDr. Steven A. Kates Ph.D., VP of Technology How do I buy shares of Arch Therapeutics? Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Arch Therapeutics' stock price today? One share of ARTH stock can currently be purchased for approximately $0.2899. How big of a company is Arch Therapeutics? Arch Therapeutics has a market capitalization of $47.53 million. Arch Therapeutics employs 8 workers across the globe. What is Arch Therapeutics' official website? The official website for Arch Therapeutics is http://www.archtherapeutics.com/. How can I contact Arch Therapeutics? Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected] MarketBeat Community Rating for Arch Therapeutics (OTCMKTS ARTH)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 148 (Vote Outperform)Underperform Votes: 164 (Vote Underperform)Total Votes: 312MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote "Outperform" if you believe ARTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARTH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: What is channel trading? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.